APRIL promotes cell-cycle progression in primary multiple myeloma cells: Influence of D-type cyclin group and translocation status

Blood

Volumn 117, Issue 3, 2011, Pages 890-901

  Quinn, John ^a   Glassford, Janet ^a   Percy, Laura ^a   Munson, Philippa ^b   Marafioti, Teresa ^b   Rodriguez Justo, Manuel ^b   Yong, Kwee ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APRIL PROTEIN; B CELL ACTIVATING FACTOR; B LYMPHOCYTE ANTIGEN; CYCLIN D1; CYCLIN D2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER CELL; CELL CYCLE G2 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL FUNCTION; CELL MATURATION; CLINICAL ARTICLE; DISEASE COURSE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL;

EID: 78751685293     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-01-264424     Document Type: Article

References (42)

1. Zhang XG, Bataille R, Widjenes J, et al. Interleukin-6 dependence of advanced malignant plasma cell dyscrasias. Cancer. 1992;69(6):1373-1376.
2. Ferlin M, Noraz N, Hertogh C, Brochier J, Taylor N, Klein B. Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway. Br J Haematol. 2000;111(2):626-634.
3. Derksen PW, Keehnen RM, Evers LM, van Oers MH, Spaargaren M, Pals ST. Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood. 2002;99(4):1405-1410. (Pubitemid 34547098)
4. Novak AJ, Darce JR, Arendt BK, et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood. 2004;103(2):689-694.
5. Moreaux J, Legouffe E, Jourdan E, et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood. 2004;103(8):3148-3157. (Pubitemid 38451693)
6. Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia. 2003;17(6):1175-1182. (Pubitemid 36722250)
7. Bergsagel PL, Kuehl WM, Zhan F. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. J Clin Oncol. 2005;23(26):6333-6338.
8. Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood. 2006;108(6):2020-2028.
9. Bergsagel PL, Kuehl WM. Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma. Immunol Rev. 2003;194:96-104.
10. Sherr CJ. D-type cyclins. Trends Biochem Sci. 1995;20(5):187-190.
11. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev. 1998;12(15):2245-2262.
12. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005;23(26):6333-6338. (Pubitemid 46218843)
13. Glassford J, Rabin N, Lam EW, et al. Functional regulation of D-type cyclins by insulin-like growth factor-I and serum in multiple myeloma cells. Br J Haematol. 2007;139(2):243-254. (Pubitemid 47493092)
14. Zlei M, Egert S, Wider D, Ihorst G, Wäsch R, Engelhardt M. Characterization of in vitro growth of multiple myeloma cells. Exp Hematol. 2007;35(10):1550-1561. (Pubitemid 47419137)
15. Moreaux J, Cremer FW, Reme T, et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood. 2005;106(3):1021-1030. (Pubitemid 41076449)
16. Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol. 2009;9(7):491-502.
17. Ingold K, Zumsteg A, Tardivel A, et al. Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med. 2005;201(9):1375-1383. (Pubitemid 40664082)
18. Tai YT, Li XF, Breitkreutz I, et al. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2006;66(13):6675-6682. (Pubitemid 44085624)
19. Moreaux J, Hose D, Jourdan M, et al. TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines. Haematologica. 2007;92(6):803-811. (Pubitemid 350155306)
20. Moreaux J, Sprynski AC, Dillon SR, et al. APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop. Eur J Haematol. 2009;83(2):119-129.
21. Kirshner J, Thulien KJ, Martin LD, et al. A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma. Blood. 2008;112(7):2935-2945.
22. Schwaller J, Schneider P, Mhawech-Fauceglia P, et al. Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness. Blood. 2007;109(1):331-338. (Pubitemid 46053074)
23. Quinn J, Glassford J, Percy L, et al. CD20-positive multiple myeloma: differential expression of cyclins D1 and D2 suggests a heterogeneous disease. Br J Haematol. 2010;149(2):150-163.
24. Jones DT, Ganeshaguru K, Anderson RJ, et al. Albumin activates the AKT signaling pathway and protects B-chronic lymphocytic leukemia cells from chlorambucil-and radiation-induced apoptosis. Blood. 2003;101(8):3174-3180. (Pubitemid 36858012)
25. Drach J, Gattringer C, Glassl H, Drach D, Huber H. The biological and clinical significance of the KI-67 growth fraction in multiple myeloma. Hematol Oncol. 1992;10(2):125-134.
26. Fonseca R, Blood EA, Oken MM, et al. Myeloma and the t(11;14)(q13;q32): evidence for a biologically defined unique subset of patients. Blood. 2002;99(10):3735-3741. (Pubitemid 34534545)
27. Huang X, Di Liberto M, Cunningham AF, et al. Homeostatic cell-cycle control by BLyS: induction of cell-cycle entry but not G1/S transition in opposition to p18INK4c and p27Kip1. Proc Natl Acad Sci U S A. 2004;101(51):17789-17794. (Pubitemid 40051965)
28. Tam SW, Theodoras AM, Shay JW, et al. Differential expression and regulation of Cyclin D1 protein in normal and tumor human cells: association with CDK4 is required for Cyclin D1 function in G1 progression. Oncogene. 1994;9(9):2663-2674.
29. Della Ragione F, Borriello A, Mastropietro S, et al. Expression of G1-phase cell cycle genes during hematopoietic lineage. Biochem Biophys Res Commun. 1997;231(1):73-76. (Pubitemid 27212111)
30. Belnoue E, Pihlgren M, McGaha TL, et al. APRIL is critical for plasmablast survival in the bone marrow and is poorly expressed by early life bone marrow stromal cells. Blood. 2008;111(5):2755-2764.
31. Benson MJ, Dillon SR, Castigli E, et al. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol. 2008;180(6):3655-3659.
32. Bossen C, Cachero TG, Tardivel A, et al. TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood. 2008;111(3):1004-1012. (Pubitemid 351213377)
33. Castigli E, Scott S, Dedeoglu F, et al. Impaired IgA class switching in APRIL-deficient mice. Proc Natl Acad Sci U S A. 2004;101(11):3903-3908. (Pubitemid 38381075)
34. Castigli E, Wilson SA, Scott S, et al. TACI and BAFF-R mediate isotype switching in B cells. J Exp Med. 2005;201(1):35-39. (Pubitemid 40130081)
35. Gupta M, Dillon SR, Ziesmer SC, et al. APRIL mediates follicular lymphoma B cell proliferation and cyclin D1 expression through PI3-kinase regulated mTOR activation. Blood. 2009;113(21):5206-5216.
36. Endo T, Nishio M, Enzler T, et al. BAFF and APRIL support chronic lymphocytic leukemia Bcell survival through activation of the canonical NF-kappaB pathway. Blood. 2007;109(2):703-710. (Pubitemid 46105972)
37. Hatada EN, Do RK, Orlofsky A, et al. NF-kappa B1 p50 is required for BLyS attenuation of apoptosis but dispensable for processing of NFkappa B2 p100 to p52 in quiescent mature B cells. J Immunol. 2003;171(2):761-838. (Pubitemid 36871386)
38. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 2007;12(2):131-144. (Pubitemid 47208626)
39. Annunziata CM, Davis RE, Demchenko Y, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 2007;12(2):115-130. (Pubitemid 47199123)
40. Ely S, Di Liberto M, Niesvizky R, et al. Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma. Cancer Res. 2005;65(24):11345-11353. (Pubitemid 41821691)
41. Schwaller J, Went P, Matthes T, et al. Paracrine promotion of tumor development by the TNF ligand APRIL in Hodgkin's disease. Leukemia. 2007;21(6):1324-1327. (Pubitemid 46831829)
42. Huard B, McKee T, Bosshard C, et al. APRIL secreted by neutrophils binds to heparan sulfate proteoglycans to create plasma cell niches in human mucosa. J Clin Invest. 2008;118(8):2887-2895.